Ae‐Ran Choi

744 citations
33 papers · 566 indexed · h-index 18
Topics
Drug Transport and Resistance Mechanisms (6 papers)SARS-CoV-2 and COVID-19 Research (4 papers)Renal Transplantation Outcomes and Treatments (4 papers)

In The Last Decade

Ae‐Ran Choi

30 papers receiving 557 citations

Peers

Ae‐Ran Choi
Comparison fields: 5 of 84
  • Molecular Biology 186
  • Infectious Diseases 143
  • Oncology 141
  • Epidemiology 99
  • Immunology 92
Replace Xavier Fonrose with:
Xavier Fonrose France
Yabo Ouyang China
TOHRU KINO Japan
Lucy Meunier France
Ping Ruan United States
Agnieszka Daca Poland
Erin Bailey United States
Beatriz Gros Spain
Masato Horikawa Japan
Kiran Dole United States
Ae‐Ran Choi relative to Xavier Fonrose France Xavier Fonrose's profile →
Citations per field
00.5×
Xavier Fonrose · 1×
Citations per year

Countries citing papers authored by Ae‐Ran Choi

Since Specialization
Citations

This map shows the geographic impact of Ae‐Ran Choi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ae‐Ran Choi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ae‐Ran Choi more than expected).

Fields of papers citing papers by Ae‐Ran Choi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ae‐Ran Choi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ae‐Ran Choi. The network helps show where Ae‐Ran Choi may publish in the future.

Co-authorship network of co-authors of Ae‐Ran Choi

This figure shows the co-authorship network connecting the top 25 collaborators of Ae‐Ran Choi. A scholar is included among the top collaborators of Ae‐Ran Choi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ae‐Ran Choi. Ae‐Ran Choi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 5
3 1
4 1
5 0
6 1
7 28
8 28
9 4
10 41
11 18
12 12
13 26
14 25
15 39
16 22
17 35
18
Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.
10
19 23
20 20

About Ae‐Ran Choi

Ae‐Ran Choi is a scholar working on Transplantation, Infectious Diseases and Biochemistry, having authored 33 papers that have together received 566 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Renal Transplantation Outcomes and Treatments (4 papers). The work is most often cited by research in Transplantation (44 citations), Infectious Diseases (143 citations) and Oncology (141 citations). Ae‐Ran Choi has collaborated with scholars based in South Korea, United States and South Africa. Frequent co-authors include Sungpil Yoon, Ju-Hwa Kim, Eun‐Jee Oh, Hyung Sik Kim, Hyeyoung Lee, Jihyang Lim, Ki Hyun Park, Kyungja Han, Yong Kee Kim and Jong‐Mi Lee. Their work appears in journals such as Blood, PLoS ONE and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026